HB0034 in Patients With Generalized Pustular Psoriasis (GPP)
NCT ID: NCT05512598
Last Updated: 2024-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
9 participants
INTERVENTIONAL
2022-11-06
2024-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
NCT06231381
Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
NCT06477536
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
NCT05531682
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
NCT06077331
A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
NCT06672393
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HB0034
Recombinant Humanized Anti-IL-36R Monoclonal antibody
HB0034
HB0034, a single dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HB0034
HB0034, a single dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A known and documented history of Generalized Pustular Psoriasis diagnosed with ERASPEN criteria
* Presenting with a moderate-severe flare of Generalized Pustular Psoriasis (GPP)
* Patients must be able to understand and sign a written informed consent document and complete study-related procedures and questionnaires.
Exclusion Criteria
* History of clinically significant opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia)
* Pregnant or Breasting feeding subject. Women with a positive pregnancy test.
* Ongoing use of prohibited psoriasis treatments
* Further exclusions criteria apply
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Huaota Biopharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhang Furen, Doc.
Role: PRINCIPAL_INVESTIGATOR
Shandong Provincial Dermatology Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermatology Hospital of Shandong First Medical University
Shandong, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HB0034-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.